Godavari Drugs Ltd

Godavari Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 04 March 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Godavari Drugs Ltd has witnessed a notable shift in its valuation parameters, moving from a very attractive to an attractive rating, reflecting improved price metrics despite a challenging market backdrop. This article analyses the recent changes in the company’s price-to-earnings and price-to-book ratios, compares them with peer averages and historical benchmarks, and assesses the implications for investors.

Godavari Drugs Ltd has seen its investment rating downgraded from Strong Sell to Sell as of 4 March 2026, reflecting a complex interplay of technical indicators, valuation metrics, financial trends, and overall quality assessments. Despite some mild improvements in technical signals, the company’s weak long-term fundamentals and flat recent financial performance have weighed heavily on investor sentiment.

Godavari Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has recently formed a Golden Cross, a significant technical indicator where the 50-day moving average (DMA) has crossed above the 200-day moving average. This development often signals a potential bullish breakout and a shift in long-term momentum, attracting investor attention despite the company’s current strong sell rating and subdued financial performance.

Godavari Drugs Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 23 February 2026. This shift reflects deteriorating technical indicators, flat financial performance, and a cautious outlook on valuation and quality metrics, signalling increased risk for investors amid challenging market conditions.

Godavari Drugs Ltd has seen its investment rating upgraded from Strong Sell to Sell, driven primarily by a marked improvement in valuation metrics despite ongoing challenges in financial performance and market returns. The pharmaceutical company’s recent assessment highlights a very attractive valuation grade, while quality, financial trends, and technical indicators remain subdued, reflecting a cautious outlook for investors.

Godavari Drugs Ltd has witnessed a notable shift in its valuation parameters, moving from an attractive to a very attractive rating, despite recent share price declines and sector headwinds. This recalibration in price-to-earnings and price-to-book value metrics positions the pharmaceutical company as a compelling consideration for investors seeking value within the Pharmaceuticals & Biotechnology sector.

Godavari Drugs Ltd., a micro-cap active pharmaceutical ingredients (API) manufacturer, reported a marginal sequential improvement in Q2 FY26 (July-September 2025), with net profit of ₹1.00 crores representing a decline of 3.85% quarter-on-quarter but an 8.26% decline year-on-year. The company, with a market capitalisation of ₹67.00 crores, continues to grapple with revenue volatility and compressed profitability margins, reflecting ongoing challenges in the API manufacturing landscape.

Godavari Drugs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 10 February 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 10 February 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Godavari Drugs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 10 February 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 30 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Godavari Drugs Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 10 February 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Godavari Drugs Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 10 February 2025, reflecting a reassessment of the company’s outlook. However, the analysis and financial metrics presented here are based on the stock’s current position as of 07 January 2026, providing investors with the latest insights into its performance and prospects.

Godavari Drugs Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 10 February 2025, reflecting a reassessment of the stock’s outlook. However, the analysis and financial metrics discussed below represent the company’s current position as of 25 December 2025, providing investors with the latest insights into its performance and prospects.

Godavari Drugs has reached a new 52-week low of Rs.69.7, marking a significant decline in its stock price amid a challenging market environment and subdued financial performance over the past year.

Godavari Drugs has reached a new 52-week low of Rs.70.31 today, marking a significant decline in its stock price amid ongoing downward momentum. The pharmaceutical company’s shares have been under pressure, reflecting a series of financial and market challenges over the past year.